J of IMAB 2012; 18(1):213-215
A Case of Long Term Survival in Woman with Metastatic Breast Cancer Treated with Trastuzumab
Deyan N. Davidov
Department of Chemotherapy, UMHAT "Dr. G. Stranski", MedicalUniversity, Pleven, Bulgaria.

ABSTRACT:
Intravenous Trastuzumab is an effective treatment for metastatic breast cancer after failure of first- line chemotherapy for patients with human epidermal growth factor 2 (HER- 2) - positive receptor. The aim of this study is to present of case of long time survival woman with metastatic breast cancer. The case is a 55- years old female. She underwent left mastectomy with axillary lymphadenectomy for breast cancer. Histological examination showed invasive ductal carcinoma, grade III, estrogen and progesterone receptor- negative, HER2- positive receptor status. Radiotherapy and six courses with antracyclines were performed as adjuvant chemotherapy. One year after the operation she was diagnosed to have lung metastases. Treatment was initiated with Trastuzumab 8 mg/kg for loading dose and 4 mg/kg maintenance dose every week. Treatment was continued for more than two years. Control computer tomography indicates stable disease. No adverse events were reported for twenty four months of Trastuzumab treatment. Treatment was stopped due to patients withdrawn. Overall survival was 31 months. This case indicate that long term Trastuzumab would be an optimal treatment for HER2- positive breast cancer patients.

Key words: Long term survival, Metastatic breast cancer, Trastuzumab.

- Download FULL TEXT ( PDF 140 KB )
Please cite this article as: Davidov DN. A Case of Long Term Survival in Woman with Metastatic Breast Cancer Treated with Trastuzumab. J of IMAB. 2012; 18(1):213-215. doi: 10.5272/jimab.2012181.213

REFERENCES:
1. Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006;4 (suppl 1): 4- 9. [PubMed]
2.  Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998; 352: 930-942. [CrossRef] [PubMed]
3. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005 Oct 15;104(8):1742–1750. [PubMed]
4.  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9;235(4785):177-182. [CrossRef] [PubMed]
5.  Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/ neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node negative breast carcinomas. J Clin Oncol. 1997 Aug;15(8):2894-2904. [PubMed]
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,  et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001 Mar;344(11):783-792. [CrossRef]] [PubMed]
7. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ., Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006 May;3(5):269-280. [CrossRef] [PubMed]
8. Bernard-Marty C, Cardoso F, Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9(6):617-632. [CrossRef] [PubMed]
9. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005 Jul 1;23(19):4265-4274. [CrossRef] [PubMed]
10. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998 Oct 29;17(17):2235-2249. [CrossRef] [PubMed]
11. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998 May;16(5):1669-1676. [PubMed]
12. Beda M, Basso U, Ghiotto C, Monfardini S: When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori 2007, 93:491-492. [PubMed]
13. Maciá Escalante S, Rodríguez Lescure Á, Pons Sanz V, Martínez Banaclocha N, Guillén Ponce C, Carrato Mena A. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol 2006 Oct;8(10):761-763. [PubMed]
14. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004 Mar 15;22(6):1063-1070. [CrossRef] [PubMed]
15. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C,  et al: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003 Jun;4(2):120-125. [CrossRef] [PubMed]
16. Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al: Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) (abstract). J Clin Oncol. (Meeting Abstracts) 2008 May;26(15 Suppl):1025.

Accepted for publication: 28 August 2011
Issue published online: 07 February 2012

back to Online Journal